Liver LDL receptor mRNA expression is decreased in human ApoB/CETP double transgenic mice and is regulated by diet as well as the cytokine oncostatin M

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 11, 1997, Pages 2948-2954

  Liu, Jingwen ^a,e   Lynda Zhang, Y ^a   Spence, Michael J ^a   Vestal, Robert E ^a,b   Wallace, Philip M ^c   Grass, David S ^d  

^a Boise VA Medical Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^d Chrysalis DNX Transgenic Sciences   (United States)

^e VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

LDL; LDL receptor; Oncostatin M; Serum cholesterol; Transgenic mice

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; ONCOSTATIN M;

ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; GENE EXPRESSION REGULATION; LIPID DIET; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 17344365409     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.11.2948     Document Type: Article

References (21)

1. Yoked M, Hammer RE, Ishibashi S, Brown MS, Goldstein JL. Diet-induced hypercholesterolemia in mice: prevention by overexpression of LDL receptors. Science. 1990;250:1273.
2. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in LDL receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest. 1993;92:883.
3. Goldstein JL, MS Brown. Regulation of the mevalonate pathway. Nature. 1990;343:425.
4. Linton MF, Farese RV Jr, Chiesa G, Grass DS, Chin P, Hammer RE, Hobbs HH, Young SG. Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). J Clin Invest. 1993;92:3029.
5. Xiong W, Zsigmond E, Gotto AM Jr, Lei KY, Chan L. Location of a low density lipoprotein-targeting domain of human apolipoprotein B-100 by expressing a minigene construct in transgenic mice. J Biol Chem. 1991;266:20893.
6. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res. 1993;34:1255.
7. Agellon LB, Wafch A, Hayek T, Moulin P, Jiang XC, Shelanski SA, Breslow JL, Tall AR. Reduced high density lipoprotein cholesterol in human cholesterol ester transfer protein transgenic mice. J Biol Chem. 1991;266:10796.
8. Marotti KR, Castle CK, Murray RW, Rehberg EF, Polites HG, Melchior GW. The role of cholesteryl ester transfer protein in primate apolipoprotein A-I metabolism: insights from studies with transgenic mice. Arterioscler Thromb. 1992;12:736.
9. Marotti KR, Castle CK, Boyle TP, Lin AH, Murray RW, Melchior GW. Severe atherosclerosis in transgenic mice expressing simian cholesterol ester transfer protein. Nature. 1993;364:73.
10. Purcell-Huynh DA, Farese RV Jr, Johnson DF, Flynn LM, Pierotti V, Newland DL, Linton MF, Sanan DA, Young SG. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J Clin Invest. 1995;95:2246.
11. Grass DS, Saini U, Felkner RH, Wallace RE, Lago WJP, Young SG, Swanson ME. Transgenic mice expressing both human apolipoprotein B and human CETP have a lipoprotein cholesterol distribution similar to that of normolipidemic humans. J Lipid Res. 1995;36:1082.
12. Jiang XC, Masucci ML, Mar J, Lin M, Walsh A, Breslow JL, Tall A. Down-regulation of mRNA for the low density lipoprotein receptor in transgenic mice containing the gene for human cholesteryl ester transfer protein: mechanism to explain accumulation of lipoprotein B particles. J Biol Chem. 1993;268:27406.
13. Corsini A, Mazzotti M, Villa A, Maggi FM, Bernini F, Romane L, Romano C, Fumagalli R, Catapano AL. Ability of the LDL receptor from several animal species to recognize the human apo B binding domain: studies with LDL from familial defective apo B-100. Atherosclerosis. 1992;93:95.
14. Zarling JM, Shoyab M, Marquardt H, Hanson MB, Lioubin MN, Todaro GJ, Oncostatin M: a growth regulator produced by differentiated lymphoma cells. Proc Natl Acad Sci U S A. 1986;83:9739.
15. Brown TJ, Lioubin MN, Marquardt H. Purification and characterization of cytostatic lymphokines produced by activated human T-lymphocytes: synergistic antiproliferative activity of transforming growth factor β1, interferon gamma, and oncostatin M for human melanoma cells. J Immunol. 1987;139:2977.
16. Grove RI, Mazzucco C, Allegretto N, Kiener PA, Spitalny G, Radka SF, Shoyab M, Antonaccio M, Warr GA. Macrophage-derived factors increase low-density lipoprotein uptake and receptor number in cultured human liver cells. J Lipid Res. 1991;32:1889.
17. Grove RI, Mazzucco CE, Radka SF, Shoyab M, Kiener PA. Oncostatin M upregulates LDL receptor in HepG2 cells by a novel mechanism. J Biol Chem. 1991;266:18194.
18. Liu J, Grove RI, Vestal RE. Oncostatin M activates the LDL receptor gene transcription in sterol-repressed liver cells. Cell Growth & Differentiation. 1994;5:1333.
19. Liu J, Streiff R, Zhang YL, Robert E, Vestal Spence, MJ, Priggs M. Novel mechanism of transcriptional activation of hepatic LDL receptor by oncostatin M. J Lipid Res. In press.
20. Malik N, Graves D, Shoyab M, Purchio AF. Amplification and expression of heterologous oncostatin M in Chinese hamster ovary cells: DNA. Cell Biol. 1992;11:453.
21. Virca GD, Northemann W, Shiels BR, Widera G, Broome S. Simplified Northern blot hybridization using 5% sodium dodecyl sulfate. Biotechniques. 1990;8:370.